Menu
GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
    • HTA Philippines Social Values Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Careers
    • Contact Us
    • Call for Nomination
    • Topic Nomination
  • AUXILIARY MENU
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
    • HTA Philippines Social Values Guide
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Careers
    • Contact Us
    • Call for Nomination
    • Topic Nomination

Non COVID-19

nimble_asset_Website-banner-Assessments

HTAC RECOMMENDATION ON THE PNF INCLUSION OF abiraterone acetate in combination with prednisone and enzalutamide for individuals with metastatic castration-resistant prostate cancer

nimble_asset_Website-banner-Assessments

HTAC RECOMMENDATION ON THE PNF INCLUSION OF REMDESIVIR FOR ADULT PATIENTS WITH COVID-19 REQUIRING HOSPITALIZATION

HTAC Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)

HTAC recommendation for the inclusion of insulin glargine non-inclusion of insulin detemir for the treatment of type 1 and type 2 diabetes mellitus in the PNF.

HTAC recommendation for eribulin in the treatment of soft tissue sarcoma patients with previous treatment of two other chemotherapeutic agents for metastatic disease

HTAC recommendation for the non-inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma

HTAC recommendation on the reinclusion of vasopressin in the PNF

Emtricitabine + Tenofovir Disoproxil Fumarate fixed-dose combination as Oral Pre-Exposure Prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-infection

HTAC recommendation on the minor inclusion of sambong 250mg tablet for anti-urolithiasis (kidney stones) in the Philippine National Formulary (PNF)